Abstract
Apoptosis is an induced and ordered process in which the cell actively participates in bringing about its own death. Dysregulation in either of the apoptotic pathways leads to various diseases including cancer, neurodegenerative disorders and autoimmunity. Bcl-2 (B cell lymphoma 2) proteins such as pro-and anti-apoptotic play a vital role in the mitochondrial pathway of apoptosis which results in cellular commitment to death or cell survival. So, therefore many small molecule antagonists that targets Bcl-2 anti-apoptotic proteins that lead to cellular survival are in their pre-clinical and clinical stages. In this review we focus on the apoptotic players of Bcl-2 group of proteins and their anti-apoptotic inhibitors.
Keywords: Apoptosis, Bcl-2 family, BH-3 Domain, Molecular pathways, Small molecule inhibitors
Current Cancer Therapy Reviews
Title:BCL-2 Family Proteins: The Mitochondrial Apoptotic Key Regulators
Volume: 8 Issue: 2
Author(s): P. Daisy and K. Saipriya
Affiliation:
Keywords: Apoptosis, Bcl-2 family, BH-3 Domain, Molecular pathways, Small molecule inhibitors
Abstract: Apoptosis is an induced and ordered process in which the cell actively participates in bringing about its own death. Dysregulation in either of the apoptotic pathways leads to various diseases including cancer, neurodegenerative disorders and autoimmunity. Bcl-2 (B cell lymphoma 2) proteins such as pro-and anti-apoptotic play a vital role in the mitochondrial pathway of apoptosis which results in cellular commitment to death or cell survival. So, therefore many small molecule antagonists that targets Bcl-2 anti-apoptotic proteins that lead to cellular survival are in their pre-clinical and clinical stages. In this review we focus on the apoptotic players of Bcl-2 group of proteins and their anti-apoptotic inhibitors.
Export Options
About this article
Cite this article as:
Daisy P. and Saipriya K., BCL-2 Family Proteins: The Mitochondrial Apoptotic Key Regulators, Current Cancer Therapy Reviews 2012; 8 (2) . https://dx.doi.org/10.2174/157339412800675414
DOI https://dx.doi.org/10.2174/157339412800675414 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue "Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics" aims to explore cutting-edge developments and innovative strategies in the field of lipid nanoparticle (LNP) technology, particularly focusing on its application in mRNA delivery. This topic has gained unprecedented attention and urgency in the wake of the COVID-19 ...read more
Current Progress in Protein Degradation and Cancer Therapy
Targeted Protein Degradation is gaining momentum in cancer therapy; it facilitates targeting undruggable proteins, overcomes cancer resistance, and avoids undesirable side effects. Thus small molecule degraders have emerged as novel therapeutic strategies. Targeted protein degradation (TPD), the process of eliminating a protein of interest holds a great promise for the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-TNF and Crohns Disease: When Should We Stop?
Current Drug Targets Interferon-Alpha in the Treatment of Multiple Myeloma
Current Drug Targets Anti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti-Cancer Therapy
Current Cancer Drug Targets Genetic Predisposition to Neonatal Tumors
Current Pediatric Reviews Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
Current Cancer Drug Targets Defective Autophagy in Fibroblasts May Contribute to Fibrogenesis in Autoimmune Processes
Current Pharmaceutical Design Death Receptors as Targets of Cancer Therapeutics
Current Cancer Drug Targets Multi or Single-Kinase Inhibitors to Counteract Drug Resistance in Cancer: What is New?
Current Medicinal Chemistry Strategy for Treatment of Helicobacter pylori Infection in Adults I. Updated Indications for Test and Eradication Therapy Suggested in 2000
Current Pharmaceutical Design The Polyhedric Abl Kinases and their Pharmacologic Inhibitors
Current Enzyme Inhibition Thalidomide Derived Immunomodulatory Drugs (IMiDs) as Potential Therapeutic Agents
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Hepatic MicroRNA Orchestra: A New Diagnostic, Prognostic and Theranostic Tool for Hepatocarcinogenesis
Mini-Reviews in Medicinal Chemistry Amino Acid Transporter-Targeted Radiotracers for Molecular Imaging in Oncology
Current Medicinal Chemistry Post-Transcriptional and Post-translational Regulation of Central Carbon Metabolic Enzymes in Cancer
Anti-Cancer Agents in Medicinal Chemistry Synthesis and in vitro Evaluation of the Anticancer Potential of New Aminoalkanol Derivatives of Xanthone
Anti-Cancer Agents in Medicinal Chemistry Molecular Targeted Approaches to Cancer Therapy and Prevention Using Chalcones
Current Cancer Drug Targets Higher Levels of Dynamin-related Protein 1 are Associated with Reduced Radiation Sensitivity of Glioblastoma Cells
Current Neurovascular Research Anticancer Drug Discovery from the Marine Environment
Recent Patents on Anti-Cancer Drug Discovery Survey of Epstein Barr Virus (EBV) Immunogenic Proteins and their Epitopes: Implications for Vaccine Preparation
Recent Patents on Anti-Infective Drug Discovery Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy